VEGFA and diabetic kidney disease: Patel et al. and Valladares et al. observed that inhibition of A2BAR activation suppressed VEGF production in glomeruli and further attenuated renal dysfunction in diabetic nephropathy; these data suggested a protective role of A2BAR antagonists in VEGF-induced diabetic nephropathy (Valladares et al., 2008; Patel and Thaker, 2014).